Emerging-market stocks rallied, paring the biggest weekly drop in two months, as countries from Brazil to India signaled they would act to support financial markets. Samsung Electronics Co. drove technology shares higher.
The MSCI Emerging Markets Index increased 1.1 percent to 932.76, trimming its weekly decline to 2.6 percent. Samsung Electronics, the world’s largest smartphone maker, jumped 3.2 percent in South Korea. Tata Motors Ltd. (TTMT), owner of Jaguar Land Rover, climbed 3.1 percent in Mumbai. India’s rupee rebounded from a record low, while the Brazilian real increased the most in almost two years. Homebuilders paced gains in Sao Paulo, driving the Ibovespa to a third weekly advance.
All 10 groups in the benchmark measure for emerging markets gained today, led by technology and industrial companies. Brazil’s central bank stepped up efforts to arrest the world’s worst currency decline, announcing a $60 billion intervention program involving currency swaps and loans. The Reserve Bank of India said yesterday that the nation’s economic and monetary policies must focus on preserving financial stability.
Hot India Stocks For 2015: Dr. Reddy’s Laboratories Ltd(RDY)
Dr. Reddy?s Laboratories Limited, together with its subsidiaries, operates as a pharmaceutical company. It produces finished dosage forms, active pharmaceutical ingredients and intermediates, and biotechnology products. The company also conducts research in the areas of cancer, diabetes, cardiovascular, inflammation, and bacterial infection. In addition, it involves in the contract manufacture generic prescription and over-the-counter products for branded and generic companies in the United States. The company primarily focuses on therapeutic categories of cardiovascular, diabetes management, gastro-intestinal, and pain management. It markets its products in India, the United States, Europe, and the Russian Federation. The company has a co-development and commercialization agreement with Rheoscience A/S for the development and commercialization of Balaglitazone/DRF 2593, a partial PPAR-gamma agonist for the treatment of type 2 diabetes; an agreement with ClinTec Internatio nal for the development of an anti-cancer compound, DRF 1042; collaboration with the National Cancer Institute in Maryland; and an agreement with Argenta Discovery Limited for the joint development and commercialization of a novel approach to the treatment of chronic obstructive pulmonary disease. It also has an agreement with 7TM Pharma for drug discovery collaboration on selected drug targets; and an agreement with GlaxoSmithKline plc to develop and market pharmaceuticals for the treatment of cardiovascular disease, diabetes, oncology, gastroenterology, and pain management. Dr. Reddy?s Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.
- [By Ben Levisohn]
Teva has dropped 7.7% to $37.85 today at 3:23 p.m. but doesn’t seem to be spreading though the generic drug space. Taro Pharmaceuticals (TARO) ha gained 1.1% to $79, while Actavis (ACT) has gained 1.2% to $156.25 and Dr. Reddy’s Laboratories (RDY) has advanced 1% to $40.24. Mylan (MYL) has dropped 0.7% to $38.40.
- [By Dan Carroll]
The company’s generic drug segment should also help push emerging market sales. Abbott markets generic pharmaceuticals outside the U.S. only, and while the division isn’t growth-oriented — sales actually fell around 2% for the quarter — it provides an entry for the company to push into lucrative new markets such as India, where generics make up the large majority of the country’s retail market. The company will face tougher competition in this industry, however: Firms such as India-based Dr. Reddy’s (NYSE: RDY ) have also pushed hard into emerging markets lately, and Dr. Reddy’s in particular should benefit from its being headquartered in one of the industry’s top locales.
- [By Benjamin Shepherd] We’re now into day 15 of the US government shutdown, as House Republicans stubbornly try to defund Obamacare. No matter what sort of deal is eventually struck, health care costs aren’t likely to come down any time soon. And that’s good news for generic drug makers.
Dr. Reddy’s Laboratories (NYSE: RDY) is one of the biggest players in generic drugs, offering more than 200 off-brand medications in the areas of cardiovascular disease, pain management and oncology, among others. In fact, this India-based company has become one of the largest makers of generics in the world, helping to drive more than 20 percent annual compounded earnings growth at the company over the past decade.
Hot India Stocks For 2015: Infosys Technologies Limited(INFY)
Infosys Ltd. provides information technology (IT) and consulting services worldwide. It offers IT services, such as application, architecture, independent validation and testing, information management, infrastructure, packaged application, SOA, systems integration, and knowledge services; product engineering services, manufacturing process and plant solutions, and product lifecycle management services; and consulting services in the areas of information and technology strategies, product innovation, next generation commerce, process excellence, and learning and complex change. The company also provides business process outsourcing solutions in the areas of business platforms, customer service outsourcing, finance and accounting, human resources outsourcing, legal services, sales and fulfillment, and sourcing and procurement outsourcing. In addition, it offers collaborative analytics solutions; digital consumer platform; Finacle universal banking solution; iProwe, a Web ac cessibility assessment product; mConnect, a real-time enterprise middleware; and research and analytical support services. Further, the company offers unified communications and collaboration solution that streamlines business processes between employees, customers, and suppliers; iTransform that helps healthcare organizations accelerate transition to new platforms; and supply chain visibility and collaboration product suite. It serves aerospace and defense, airlines, automotive, banking, capital markets, communication services, consumer packaged goods, manufacturing, education, energy, healthcare, high technology, hospitality and leisure, insurance, life sciences, logistics and distribution, publishing, resources, utilities, and retail industries. Infosys Ltd. has a strategic partnership with Alstom SA. The company was formerly known as Infosys Technologies Limited and changed its name to Infosys Ltd. on June 16, 2011. Infosys Ltd. was founded in 1981 and is headquartered i n Bengaluru, India.
- [By Robert Martin]
Infosys (INFY), Housing Development Finance and Reliance Industries LTD are the top three holdings, with weightings between 8% and 10.5%. Of course, just about any India ETF will have a heavy allocation to Infosys and Reliance. However, INDA dedicates a lower percentage to energy than some of the alternatives, and instead leans more on IT and consumer spending.
- [By Aaron Smith]
The government accused software developer Infosys (INFY) of using workers with B-1 visas, which only allow temporary entry into the U.S. for business purposes, to perform skilled labor jobs.
- [By Brian Stoffel]
That helps explain why Accenture and IBM, the industry’s two biggest players, have been able to gobble up so much market share. But there’s a second tier of technology-consultants — in terms of sheer size — as well. That’s where Cognizant, as well as its main competition — Infosys (NYSE: INFY ) and Wipro (NYSE: WIT ) — come in to play.
- [By Michael Flannelly]
Shares of Infosys Ltd (INFY) spiked in pre-market trading on Friday after the software company posted second quarter earnings and revenues that beat Wall Street expectations.
The India-based company posted a second quarter net income of $383 million, or 67 cents per share, down from $431 million, or 75 cents per share, posted in the same period last year.
The company’s earnings per American Depository Share, or ADR, came in at 73 cents per share. According to analysts at Thomson Reuters, the company was expected to earn 70 cents per share in the quarter.
Infosys’ quarterly revenues came in at $2.066 billion, up from the $1.797 billion posted in the same quarter last year. On average, analysts were expecting the company to see $2.01 billion in revenues.
“During the quarter we witnessed broad-based volume growth, robust client additions, five large deal wins and increased sales momentum of our big data and cloud offerings. This growth is a result of our focus on execution, which helps our clients achieve their objectives.” said S. D. Shibulal, CEO and Managing Director.
“We will continue with planned investments and initiatives to explore new avenues of growth. We remain watchful of the sustainability of improving global economic fundamentals”, he added.
Looking ahead, the company sees revenues growing between 9% and 10% in fiscal 2014.
Infosys shares were up $2.72, or 5.41%, during pre-market trading on Friday. The stock is up 18.87% year-to-date.
Hot India Stocks For 2015: Stewart Information Services Corporation(STC)
Stewart Information Services Corporation provides title insurance and related information services required for settlement by the real estate and mortgage industries. It operates in two segments, Title Insurance-Related Services and Real Estate Information. The Title Insurance-Related Services segment offers services that include searching for and examining documents, such as deeds, mortgages, wills, divorce decrees, court judgments, liens, paving assessments, and tax records, as well as provides titles insurance for residential and commercial properties, undeveloped acreage, farms, ranches, and water rights. This segment serves attorneys, builders, developers, home buyers and home sellers, lenders, and real estate brokers. The Real Estate Information segment offers products and services, which primarily include lender services, title technology, foreign and domestic government services, mapping, title information, Internal Revenue Code Section 1031 tax-deferred property e xchanges, pre-employment services, and online filing and transaction management. Its customers include mortgage lenders and servicers, mortgage brokers, mortgage investors, government entities, commercial and residential real estate agents, land developers, builders, title insurance agencies, and others interested in obtaining property information, as well as accountants, attorneys, investors, and employers. The company has operations primarily in the United States, Canada, the United Kingdom, central Europe, Mexico, central America, and Australia. Stewart Information Services Corporation was founded in 1893 and is based in Houston, Texas.
- [By James Fink]
My housing pick is Houston-based Stewart Information Services (STC), a 120-year-old real estate business founded in 1893, that is still owned and managed by the founding family.
- [By Ben Levisohn]
Tower Group has dropped 12% to $3.88 today at 11:39 a.m., while Stewart Information Services (STC) has dipped 0.1% to $31.16, the Navigators Group (NAVG) has fallen 1.4% to $54.78 and HCI Group (HCI) has gained 1% to $38.16.
- [By Ben Levisohn]
Tower Group has dropped 40% to $4.43 today, and some other small insurers are also getting dinged this morning. HCI Group (HCI) has fallen 1.8% to $39.36, Stewart Information Services (STC) has declined 0.7% to $31.36 and the Navigators Group (NAVG) has ticked down 0.4% to $56.10.
Hot India Stocks For 2015: Tata Motors Ltd(TTM)
Tata Motors Limited, an automobile company, engages in the manufacture and sale of commercial and passenger vehicles primarily in India. The company offers cars, utility vehicles, trucks, buses and coaches, and defense vehicles, as well as develops electric and hybrid vehicles for personal and public transportation. It also involves in distributing and marketing cars; and financing the vehicles sold by the company. In addition, the company engages in the provision of engineering and automotive solutions, as well as machine tools and factory automation solutions; construction equipment manufacturing; automotive vehicle components manufacturing and supply chain activities; tooling and plastic and electronic components for automotive and computer applications; and automotive retailing and service operations. It offers its products and services through its dealership, sales, services, and spare parts network. The company also markets its commercial and passenger vehicles in Eu rope, Africa, the Middle East, South East Asia, South Asia, and South America. The company was formerly known as Tata Engineering and Locomotive Company Limited and changed its name to Tata Motors Limited in July 2003. Tata Motors Limited was founded in 1945 and is based in Mumbai, India.
- [By Paul Ausick]
Among car makers, the Cadillac brand from General Motors Co. (NYSE: GM), the Lincoln brand from Ford Motor Co. (NYSE: F), and Toyota Motor Corp.’s (NYSE: TM) Lexus brand make the list, as does Jaguar, which is owned by India’s Tata Motors Ltd. (NYSE: TTM).
- [By Sophia Yan]
Shares of Tata Motors (TTM) tumbled almost 5% in morning trading in Mumbai as investors reacted to news of Slym’s death. Tata Motors also owns Jaguar and Land Rover brands.
- [By Trey Thoelcke]
The rise of VW could hit GM particularly hard, both in terms of reputation and in earnings. GM said it was looking to introduce four new Chevrolet models in China next year, as well as to expand its low-cost Baojun brand. Chinese buyers could already be looking elsewhere though, given the rise of VW and of Tata Motors Ltd. (NYSE: TTM), which sells cars under the Jaguar and Range Rover brands. Sales of Tata vehicles have risen sharply in the past year, and the company is set to begin producing cars in China.
- [By James Well]
Pfizer’s Net Income Growth Is Increasing Leading to Increase in Its Operating Margins
Net incomes and operating margins of a company give some insights into its financial health. Pfizer’s net income growth has accelerated this year. In fact, when compared with its direct competitors like Merck, Novartis, and Sanofi, the rate of increase of net income growth trailing twelve months (TTM) is greatest at Pfizer with $10.68 billion followed by Novartis with $9.37 billion while Merck and Sanofi lagged behind with $4.53 billion and $4.05 billion respectively. Really, rather than increasing, there has been a decrease in Merck’s and Sanofi’s net incomes this year which should be a source of concern for investors. A healthy operating margin shows that a company is earning more per dollar of sales and, hence, able to pay for its fixed costs including interest on debt.